Biotechnology
US rare disease drug developer Mirum Pharmaceuticals today announced its entry into a definitive agreement to acquire Bluejay Therapeutics, a privately held biotechnology company focused on viral and liver diseases. 8 December 2025
Biotechnology
Shanghai-based biotech OTR Therapeutics has emerged from stealth and announced the successful completion of a $100 million Series A financing closed in June 2025. 8 December 2025
Biotechnology
During Blood Cancer Awareness Month, Guy Martin, news editor at The Pharma Letter, sat down with Dr Hanbali to discuss his experiences treating patients with CAR T-cell therapy in the Middle East. 8 December 2025
Biotechnology
Swiss incubator Xlife Sciences today announced that Mexico-based Grupo Landsteiner has signed a binding framework to acquire 12 of Xlife Sciences’ advanced biotech, medtech and digital health projects for a total of $450 million, payable in Landsteiner shares. 8 December 2025
Biotechnology
Dutch biotech Pan Cancer T has raised 10 million euros ($11 million) to advance its lead cell therapy, PCT1:CO-STIM, into a first-in-human trial for women with triple-negative breast cancer. The round combines 5 million euros from existing investors and a 5 million euro government-backed loan. 8 December 2025
Most Read
Features
Company Spotlight
A clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies.
Recent news
Biotechnology
The cell and gene therapy (CGT) sector is undergoing a transition as companies navigate a more selective and strategy-driven funding landscape, according to an analysis by the pharma strategic intelligence team at and pharma analytics company. GlobalData. 9 December 2025
Pharmaceutical
Italian pharma major Recordati’s rare diseases subsidiary announced the presentation of new data detailing advances in the understanding of Castleman disease (CD), a group of rare immune system disorders characterized by abnormal lymph node enlargement and systemic inflammatory symptoms that can be potentially life-threatening. In a series of poster presentations at the 67th American Society of Hematology Annual Meeting (ASH) Annual Meeting in Orlando, Florida. 9 December 2025
Biotechnology
Gene therapy company uniQure last week received final minutes from the US Food and Drug Administration (FDA) regarding its pre-Biologics License Application (BLA) meeting held in late October to discuss the company’s application for AMT-130 in Huntington’s disease (HD). 8 December 2025
Biotechnology
Danish biotech Genmab has announced primary data from the pivotal Phase III EPCORE FL-1 study of fixed duration Epkinly (epcoritamab-bysp) alongside rituximab and lenalidomide (Epkinly + R2) in adults with relapsed or refractory (R/R) follicular lymphoma (FL). 8 December 2025
Biotechnology
US rare disease drug developer Mirum Pharmaceuticals today announced its entry into a definitive agreement to acquire Bluejay Therapeutics, a privately held biotechnology company focused on viral and liver diseases. 8 December 2025
Refine Search
In Brief
Pharmaceutical
22 November 2025 US pharma giant Eli Lilly’s weight-loss drugs have made it the first pharma company to hit a $1 trillion market valuation, a sharp turnaround from this summer when its stock was hit by disappointing results for a new obesity pill orforglipron, according to the Financial Times.
Generics
18 November 2025 India’s Zydus Lifesciences has received final approval from the US Food and Drug Administration (FDA) for diroximel fumarate delayed-release capsules, 231mg (Biogen’s Vumerity delayed-release capsules, 231mg).
Conferences
12 January 2026 15 January 2026 California, USA, The Westin St. Francis
4 February 2026 6 February 2025 New Jersey, USA, Newark Liberty International Airport Marriott
3 February 2026 5 February 2026 Massachusetts, USA, Hyatt Regency Boston Harbor
2 February 2026 5 February 2026 Florida, USA, Rosen Shingle Creek
2 February 2026 3 February 2026 California, USA, Hilton San Diego Bayfront
29 January 2026 1 February 2026 Cape Town, South Africa, Cape Town International Convention Centre
More Events
Insights
Pharmaceutical
An Expert View from Alistair Henry, executive vice president, chief scientific officer and head of patient solutions, UCB. 7 December 2025
Pharmaceutical
The accelerated approval pathway has long represented one of the US Food and Drug Administration’s (FDA) most important tools for speeding access to promising therapies. 7 December 2025
Generics
India’s pharmaceutical recalls are drawing global attention, as the US Food and Drug Administration (FDA) recently announced a nationwide recall of over 140,000 bottles of Indian-made atorvastatin, a widely prescribed cholesterol-lowering drug. 1 December 2025
Pharmaceutical
Pulmonary arterial hypertension (PAH) is a rare, progressive, and often fatal cardiopulmonary condition characterized by pulmonary vascular remodeling and progressive narrowing, leading to increased pulmonary vascular resistance and pulmonary arterial pressure. 1 December 2025
Pharmaceutical
International understanding of China’s arrival as a leading player on the world stage as an innovator of new medicines is now ubiquitous. 29 November 2025
Biotechnology
Chinese biotech companies are pivoting from "fast-follow" to "smart" first-in-class (FIC) innovation, a shift that is reshaping global licensing deals and driving multinational corporations (MNCs) to integrate more deeply with China’s R&D ecosystem. 26 November 2025
Pharmaceutical
In the last week, the European Medicines Agency, Italy’s Agenzia Italiana del Farmaco and China’s National Medical Products Administration have all moved on new therapies, pricing and traditional medicine standards, keeping pipelines and formularies in steady flux. 25 November 2025
One to Watch Companies
One to watch
A privately-held French biotech advancing a clinical pipeline of gamma delta T-cell-focused antibodies for cancer and autoimmune diseases.
One to watch
MaaT Pharma, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases.
One to watch
Privately-held GAIA is focused on the development of evidence-based, safe and accessible AI-powered digital therapeutics (DTx) that help patients restore and maintain their mental and physical health.
One to watch
Exsilio Therapeutics is developing genomic medicines that can be delivered in lipid nanoparticles to durably and safely treat a broad range of diseases, including genetic diseases, cancer, and autoimmune conditions.
Boardroom
Pharmaceutical
Danish allergy immunotherapy specialist ALK-Abello has appointed Edward Jordan as new executive vice president (EVP) and head of commercial operations in North America, effective January 5, 2026. 3 December 2025
Biotechnology
Trimtech Therapeutics, a UK biotech developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced the appointment of Alison Lawton as chairwoman of its board of directors. 2 December 2025
Biotechnology
Privately-held German biotech Tacalyx has appointed Jean Engela as chief executive (CEO). 2 December 2025
Pharmaceutical
UK-based NRG Therapeutics has announced the expansion of its team with the appointment of Paul Thompson as chief development officer (CDO). 1 December 2025
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze